Studying new antibiotics for multidrug resistant infections: Are today's patients paying for unproved future benefits?

BMJ (Online)

Volumn 360, Issue , 2018, Pages

  Powers, John H ^a   Evans, Scott R ^b   Kesselheim, Aaron S ^c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NEW DRUG; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BIOLOGICAL ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL OUTCOME; DRUG DEVELOPMENT; HUMAN; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; FORECASTING; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FORECASTING; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85042530483     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k587     Document Type: Article

References (58)

1. Mauri L, D'Agostino RBSr. Challenges in the design and interpretation of noninferiority trials. N Engl J Med 2017;377:1357-67. 10.1056/NEJMra1510063. 28976859
2. US Food and Drug Administration. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. FDA, 2015.
3. 112th United States Congress. Generating Antibiotic Incentives Now (GAIN) Act 2011. https://www.gpo.gov/fdsys/pkg/BILLS-112s1734is/pdf/BILLS-112s1734is.pdf.
4. US Food and Drug Administration. Expedited programs for serious conditions - drug and biologics 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
5. Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the fight against multidrug-resistant bacteria? a review of US Food and Drug Administration-approved antibiotics, 2010-2015. Ann Intern Med 2016;165:363-72. 10.7326/M16-0291. 27239977
6. Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis 2017;65:141-6. 10.1093/cid/cix246. 29017263
7. Nambiar S, Laessig K, Toerner J, Farley J, Cox E. Antibacterial drug development: challenges, recent developments, and future considerations. Clin Pharmacol Ther 2014;96:147-9. 10.1038/clpt.2014.116. 25056394
8. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013;13:665-71. 10.1016/S1473-3099(13)70081-1. 23622939
9. Boucher HW, Cosgrove SE, Cox E, Talbot GH. The fight against multidrug-resistant bacteria. Ann Intern Med 2017;166:78-9. 10.7326/L16-0584. 28030674
10. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013;13:269-75. 10.1016/S1473-3099(12)70293-1. 23332713
11. Friedman LM, DeMets D. Fundamentals of Clinical Trials. Springer, 2015.
12. Doshi P, Hur P, Jones M, et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern Med 2017;177:1-8. 10.1001/jamainternmed.2017.3820. 28828473
13. DiNubile MJ. Noninferior antibiotics: when is "not bad" "good enough"?Open Forum Infect Dis 2016;3:ofw110. 10.1093/ofid/ofw110. 27382597
14. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709. 10.1093/cid/cis270 22467668
15. US Food and Drug Administration. Ceftazidime-avibactam (Avycaz) prescribing information. 2015.http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/206494lbl.pdf
16. Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014;59:51-61. 10.1093/cid/ciu219 24723282
17. FDA. Televancin (Vibativ) Prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022110s011lbl.pdf.
18. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008;46:1142-51. 10.1086/533441 18444848
19. US Food and Drug Administration. Transcript of Anti-Infective Drugs Advisory Committee. Cethromycin. 2 Jun 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM176366. pdf.
20. US Food and Drug Administration. Transcript of Anti-Infective Drugs Advisory Committee. Oritavancin. 19 Nov 2008.
21. US Food and Drug Administration. Transcript of Anti-infective Drugs Advisory Committee. Iclaprim. 20 Nov 2008.
22. Diacon AH, Pym A, Grobusch MP, et al. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014;371:723-32. 10.1056/NEJMoa1313865 25140958
23. Johnson S, Louie TJ, Gerding DN, et al. Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014;59:345-54. 10.1093/cid/ciu313 24799326
24. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP3rd, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006;144:415-20. 10.7326/0003-4819-144-6-200503210-00121 16481451
25. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61. 10.1056/NEJMoa055191 16510739
26. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-44. 10.7326/0003-4819-136-11-200206040-00013 12044132
27. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011;204:340-7. 10.1093/infdis/jir270. 21742831
28. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2013;19:1163-8. 10.1111/1469-0691.12168. 23441652
29. Holland TL, Fowler VGJr. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?J Infect Dis 2011;204:329-31. 10.1093/infdis/jir275. 21742827
30. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709. 10.1093/cid/cis270. 22467668
31. Fleming TR, Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis 2008;47(Suppl 3):S108-20. 10.1086/591390. 18986275
32. International Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use. Choice of control group and related issues in clinical trials 2000. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E10/Step4/E10-Guideline.pdf.
33. Humphries RM, Yang S, Hemarajata P, et al. first report of ceftazidime-avibactam resistance in a kpc-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2015;59:6605-7. 10.1128/AAC.01165-15. 26195508
34. Projan SJ. Why is big pharma getting out of antibacterial drug discovery?Curr Opin Microbiol 2003;6:427-30. 10.1016/j.mib.2003.08.003 14572532
35. US Department of Health and Human Services. Ethical principles and guidelines for the protection of human subjects of research: the Belmont Report 1979. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html.
36. World Medical Association. Declaration of Helsinki 2013. http://www.wma.net/en/30publications/10policies/b3/.
37. US Government Printing Office. Statement regarding the effectiveness of human drug products and devices. Fed Regist 1995;60:39180-1.
38. Clinton WJG, Reinventing Regulation Act. 1995.http://catalog.hathitrust.org/Record/003002695.
39. Committee for Medicinal Products for Human UseEfficacy Working PartyCommittee for Release for Consultation. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med 2006;25:1628-38. 10.1002/sim.2584. 16639773
40. Knottnerus BJ, Geerlings SE, Moll van Charante EP, ter Riet G. Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study. BMC Fam Pract 2013;14:71. 10.1186/1471-2296-14-71. 23721260
41. Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235-44. 10.1056/NEJMoa1703058. 28528569
42. Singer M. Antibiotics for sepsis: does each hour really count, or is it incestuous amplification?Am J Respir Crit Care Med 2017;196:800-2. 10.1164/rccm.201703-0621ED. 28504905
43. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-82. 10.1136/bmj.2.4582.769 18890300
44. Sukkar E. Why are there so few antibiotics in the pipeline. Pharmaceutical Journal 2013.http://www.pharmaceutical-journal.com/news-and-analysis/features/why-are-thereso-few-antibiotics-in-the-research-and-development-pipeline/11130209.article.
45. US House of Representatives. HR 6: 21st Century Cures bill 2015. http://docs.house.gov/billsthisweek/20150706/CPRT-114-HPRT-RU00-HR6.pdf.
46. US Food and Drug Administration. Press release: FDA approves new antibacterial drug Avycaz (ceftazidime-avibactam), 26 Feb 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm.
47. US Food and Drug Administration. 22 studies where phase 2 and phase 3 trials had divergent results. 2017. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM535780.pdf.
48. Lodise T, Rosenkranz S, Finnemeyer M, et al. The emperor's new clothes: prospective observational evaluation of the association between the day 2 vancomycin exposureand failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE). IDWeek, 2017:Abstract 985.
49. Lux LJ, Posey RE, Daniels LS, et al. Pharmacokinetic/pharmacodynamic measures for guiding antibiotic treatment for hospital-acquired pneumonia 2014. http://www.ncbi.nlm. nih.gov/pubmed/25577937.
50. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/index.html.
51. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349-58. 10.1093/cid/cit253. 23616495
52. van Duin D, Lok JJ, Earley M, et al. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis 2018;66:163-71. 10.1093/cid/cix783.
53. Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors - three and counting. Cancer Discov 2013;3:20-3. 10.1158/2159-8290.CD-12-0514. 23319766
54. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27. 10.1146/annurev.med.53.082901.103929. 11818492
55. Powers JH. Commentary: How to encourage more diagnostics for infectious diseases. BMJ 2016;354:i4744. 10.1136/bmj.i4744. 27604999
56. Takebe N, McShane L, Conley B. Biomarkers: exceptional responders-discovering predictive biomarkers. Nat Rev Clin Oncol 2015;12:132-4. 10.1038/nrclinonc.2015.19. 25687910
57. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for days of antibiotic risk (RADAR). Clin Infect Dis 2015;61:800-6. 10.1093/cid/civ495.
58. Evans SR, Follmann D. Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation.Stat Biopharm Res 2016;8:386-93. 10.1080/19466315.2016.1207561. 28435515